文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向CXCR4/CXCL12轴:[177Lu]Lu-DOTAGA.(SA.FAPi)2联合CXCR4拮抗剂在三阴性乳腺癌中的应用

Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-04-08

该临床前研究探讨了FAP靶向放射性药物[177Lu]Lu-DOTAGA.(SA.FAPi)2联合CXCR4拮抗剂AMD3100在三阴性乳腺癌(TNBC)小鼠模型中的可行性与疗效。公共数据库分析显示CAF评分与TNBC患者生存负相关(p<0.05),且肿瘤中CXCR4和FAP表达均显著高于正常组织。联合治疗在细胞水平显著抑制增殖、迁移和集落形成,在4T1肿瘤模型中表现出协同效应并减少MDSC数量,主要器官毒性最小。

要点

  • CAF评分与TNBC患者生存负相关(p<0.05),肿瘤中CXCR4和FAP表达均显著高于正常组织。
  • 联合治疗在细胞水平显著抑制增殖、迁移和集落形成,在4T1模型中表现协同效应并减少MDSC。
  • PET/CT显示治疗后第13天18F-FDG和第14天[18F]AlF-NOTA-FAPI-04肿瘤摄取最低,后续逐渐升高。

核心结论

  • 作者认为[177Lu]Lu-DOTAGA.(SA.FAPi)2联合AMD3100是治疗TNBC的可行方案,主要器官毒性最小。

研究设计与样本

  • 临床前研究:公共数据库分析CAF评分与TNBC预后及FAP、CXCR4表达;体外采用BALB/3T3成纤维细胞和4T1小鼠乳腺癌细胞评估增殖、迁移和集落形成;体内采用TNBC小鼠模型,通过系列18F-FDG、[18F]AlF-NOTA-FAPI-04和[68Ga]Ga-DOTA-Pentixafor PET/CT纵向监测疗效,并用免疫组化验证。

主要发现

  • CAF评分与TNBC患者生存负相关(p<0.05),肿瘤中CXCR4和FAP表达均显著高于正常组织。
  • 联合治疗显著抑制细胞增殖、迁移和集落形成,在4T1肿瘤模型中表现协同效应并减少MDSC数量。
  • PET/CT显示治疗后第13天18F-FDG和第14天[18F]AlF-NOTA-FAPI-04肿瘤摄取最低,后续时间点均逐渐升高;Ki-67、α-SMA和CXCL12免疫组化呈相似趋势。
  • 治疗毒性评估显示主要器官(心、肺、肝、肾、脾)毒性最小。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiopharmaceutical therapies targeting fibroblast activation protein (FAP) have shown promising efficacy against many tumor types. But radiopharmaceuticals alone in most cases are insufficient to completely eradicate tumor cells, which can partially be attributed to the protective interplay between tumor cells and cancer-associated fibroblasts (CAFs). The C-X-C chemokine receptor type 4/C-X-C motif chemokine 12 (CXCR4/CXCL12) interaction plays an important role in orchestrating tumor cells and CAFs. We hereby investigated the feasibility and efficacy of [177Lu]Lu-DOTAGA.(SA.FAPi)2, a FAP-targeting radiopharmaceutical, in combination with AMD3100, a CXCR4 antagonist, in a preclinical murine model of triple-negative breast cancer (TNBC). METHODS: Public database was first interrogated to reveal the correlation between CAFs' scores and the prognosis of TNBC patients, as well as the expression levels of FAP and CXCR4 in normal tissues and tumors. In vitro therapeutic efficacy regarding cell proliferation, migration, and colony formation was assessed in BALB/3T3 fibroblasts and 4T1 murine breast cancer cells. In vivo therapeutic efficacy was longitudinally monitored using serial 18F-FDG, [18F]AlF-NOTA-FAPI-04, and [68Ga]Ga-DOTA-Pentixafor PET/CT scans and validated using tumor sections through immunohistochemical staining of Ki-67, α-SMA, CXCR4, and CXCL12. Intratumoral abundance of myeloid-derived suppressive cells (MDSCs) was analyzed using flow cytometry in accordance with the PET/CT schedules. Treatment toxicity was evaluated by examining major organs including heart, lung, liver, kidney, and spleen. RESULTS: CAFs' scores negatively correlated with the survival of TNBC patients (p < 0.05). The expression of CXCR4 and FAP was both significantly higher in tumors than in normal tissues. The combination of [177Lu]Lu-DOTAGA.(SA.FAPi)2 and AMD3100 significantly suppressed cell proliferation, migration, and colony formation in cell culture, and exhibited synergistic effects in 4T1 tumor models along with a decreased number of MDSCs. PET/CT imaging revealed lowest tumor accumulation of 18F-FDG and [18F]AlF-NOTA-FAPI-04 on day 13 and day 14 after treatment started, both of which gradually increased at later time points. A similar trend was observed in the IHC staining of Ki-67, α-SMA, and CXCL12. CONCLUSION: The combination of [177Lu]Lu-DOTAGA.(SA.FAPi)2 and AMD3100 is a feasible treatment against TNBC with minimal toxicity in main organs.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bao G, Wang Z, Liu L, et al. Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587644. doi:10.1007/s00259-024-06704-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。